The Board of Directors of NEOGEN Chemicals is scheduled to meet on February 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Q3 2026). The board will also evaluate and approve a proposal for raising funds through the issuance of equity shares, convertible instruments, or other securities. The trading window closure commenced on January 1, 2026.
Board Meeting for Q3 2026 Results
A meeting of the Board of Directors of NEOGEN Chemicals Limited is scheduled for February 11, 2026. The primary agenda is to review and approve the unaudited standalone and consolidated financial results of the company for the quarter and nine months that ended on December 31, 2025. This period corresponds to the third quarter (Q3) of the Indian Financial Year 2026.
Fundraising Proposal on the Table
In addition to the quarterly results, the Board will also be evaluating and potentially approving a proposal for raising funds. The company is considering various options including the issuance of equity shares, fully or partly convertible instruments, non-convertible instruments including debenture warrants, or any combination thereof. These instruments may be offered through various means including public issue, qualified institutional placements, or preferential issues, subject to necessary approvals.
Trading Window Closure
As previously announced on December 27, 2025, the trading window closure period for insiders commenced on January 1, 2026. This period will end 48 hours after the declaration of the Q3 2026 financial results. This is in accordance with regulations to prevent insider trading.
Source: BSE
